Treatment with PPAR agonist (e.g. rosiglitazone) showed enhanced RBCs clearance by increasing CD36 expression and phagocytosis both in vitro and in vivo and in turn promoting hematoma resolution 10. This evidence concerns the gene CD36 and hematoma.